MRNA (nucleoside-2'-O-)-methyltransferase

Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020

Retrieved on: 
Thursday, October 15, 2020
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Branches of biology, Life sciences, Biology, Medical research, Moderna, Vaccines, RNA, Messenger RNA, mRNA (guanine-N7-)-methyltransferase, MRNA (nucleoside-2'-O-)-methyltransferase

ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.

Key Points: 
  • ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.
  • To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 1938847.
  • A webcast of the call will also be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Wednesday, September 16, 2020
Infectious diseases, Genetics, Clinical trials, Cardiology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Branches of biology, Life sciences, Biotechnology, RNA, Medical research, Moderna, Vaccines, Gene expression, Molecular genetics, Messenger RNA, mRNA (guanine-N7-)-methyltransferase, MRNA (nucleoside-2'-O-)-methyltransferase, Moderna, Chiesi Group

Chiesi Group will lead development and worldwide commercialization activities and will fund all expenses related to the collaboration.

Key Points: 
  • Chiesi Group will lead development and worldwide commercialization activities and will fund all expenses related to the collaboration.
  • We are excited to begin this collaboration with Chiesi Group, which provides the opportunity to further leverage our mRNA and delivery technology, said Stephen Hoge, M.D., President of Moderna.
  • Chiesi Group is at the forefront of innovation and discovery of novel therapies for people affected by diseases with high unmet medical need, said Ugo Di Francesco, Chief Executive Officer of Chiesi Group.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 5, 2020
Research, Infectious diseases, Genetics, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Branches of biology, Life sciences, Biotechnology, Moderna, Gene expression, RNA, RNA splicing, Messenger RNA, MRNA (nucleoside-2'-O-)-methyltransferase, mRNA (guanine-N7-)-methyltransferase, Vaccine

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results and provided business updates for the second quarter of 2020 and highlighted pipeline progress.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results and provided business updates for the second quarter of 2020 and highlighted pipeline progress.
  • Despite COVID-19 disruptions, the Company expects that it is on track for an interim data readout from the Phase 2 study expected in the third quarter of 2020.
  • Positive data from an interim analysis are now available for the 100 g and 250 g dose cohorts after the second vaccination (Day 57).
  • A webcast of the call will also be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .

Moderna to Host Manufacturing & Digital Day on March 4, 2020

Retrieved on: 
Wednesday, February 26, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Branches of biology, Moderna, Molecular biology, Life sciences, RNA, Messenger RNA, Damiani, mRNA (guanine-N7-)-methyltransferase, Manufacturing, MESSENGER, MRNA (nucleoside-2'-O-)-methyltransferase

ET on Wednesday, March 4 at the Companys manufacturing facility in Norwood, Massachusetts.

Key Points: 
  • ET on Wednesday, March 4 at the Companys manufacturing facility in Norwood, Massachusetts.
  • Modernas Manufacturing & Digital Day will include presentations from Stphane Bancel, Chief Executive Officer; Juan Andres, Chief Technical Operations and Quality Officer; Marcello Damiani, Chief Digital and Operational Excellence Officer and key opinion leaders with a focus on the Companys manufacturing and digital efforts.
  • A live webcast will be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.